Navigation Links
Cord Blood America New Las Vegas Stem Cell Laboratory Scheduled for Opening in 4th Quarter 2009
Date:8/11/2009

SANTA MONICA, Calif. and LAS VEGAS, Aug. 11 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), one of the largest umbilical cord blood stem cell preservation companies (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that work has begun at its new, 17,000 square foot facility in Las Vegas for conversion into a state-of-the-art laboratory for the storage of stem cells and for research and development.

"Our target for having a cord blood processing lab in operation, a testing lab, and a cryogenic storage area is the fourth quarter of 2009. This will complete Phase One of the construction. Currently architectural plans are completed and needed demolition of parts of the interior building is underway," said Matthew Schissler, CEO and founder of Cord Blood America.

"Phase Two will involve building out of the largest cryogenic facilities in the country, as well as a research laboratory, additional processing labs and a clean room," Mr. Schissler said. "Completion is expected in 2010."

Cord Blood America recently announced it is opening a state-of-the-art laboratory for the storage of multiple stem cell products, including umbilical cord blood stem cells, in Las Vegas. The lab will be used to process and store umbilical cord blood stem cells, to store other forms of stem cells such as stem cells from the peripheral blood stream and adipose tissues, and for research and product development.

Dr. Geoffrey John O'Neill, author or co-author of more than 75 publications about stem cells, and former Laboratory and Scientific/Medical Director for Cryo-Cell International Inc. in Florida, will serve as Laboratory Director. Brian Pockett, with more than 30 years professional experience in operations, business development, marketing, sales and financial and grant development, including serving as a consultant on global distribution, product development, commercialization, investment and intellectual properties for some of the largest companies in the U.S., is Vice President of Laboratory Operations.

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as ``anticipate,'' ``believe,'' ``expect,'' ``future,'' ``intend,'' ``plan,'' and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

    CONTACT:
    Paul Knopick
    E & E Communications
    949/707-5365
    pknopick@eandecommunications.com


'/>"/>
SOURCE Cord Blood America, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cord Blood America Retires $2.53M Obligation
2. Stem Cell Cord Blood Banking Is Huge Global Business for Hospitals, Says CEO of Bio-Matrix Scientific Group Inc.
3. Cellular Dynamics International Reprograms Blood Cells into Stem Cells
4. Cord Blood America Secured $7.5 Million Investment For Series A Preferred Stock
5. Exosome Diagnostics and DxS Diagnostic Innovations Collaborate to Develop Blood-Based Tests for Key Cancer Mutations
6. Cord Blood America Continues International Expansion
7. Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C
8. Researchers solve bloodcurdling mystery
9. Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma
10. Cord Blood America Says Debt Reduced $4.194 Million in 2009
11. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017  GlobeImmune, Inc. today announced it has ... of 12,835,490 shares of its common stock to NantCell, ... connection with the sale of its common stock, NantCell ... issue to GlobeImmune 200,000 shares, an estimated $2.0 million ... "We are pleased to enter into this strategic agreement ...
(Date:3/23/2017)... March 23, 2017 NetworkNewsWire Editorial Coverage  ... Cancer ... significant strain on health care systems, in terms of costs ... so too does the development of innovative and efficient therapies ... Among the many types of cancer treatments, a growing number ...
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced Polymer Monitoring Technologies ... Dr. Sigmund “Sig” Floyd as Vice President ? Global Business Development. Dr. Floyd ... , “Dr. Floyd’s career has spanned 30 years in the chemicals and equipment ...
(Date:3/22/2017)... 2017  UBM and the Massachusetts Medical Device ... partnership and the third annual Massachusetts Medtech Week. Massachusetts ... st Annual MassMEDIC Conference held in conjunction ... 2017. MassMEDIC will feature a ... and CEO, Scott Whitaker , at its ...
Breaking Biology Technology:
(Date:2/27/2017)... --  Strategic Cyber Ventures , the industry,s first cybersecurity ... million investment in  Polarity , the first commercial human ... based and is led by cybersecurity veterans Tom ... Gula , also a longtime cybersecurity veteran and founder ... A round of funding. This new funding will be ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):